CD Skripsi

Sintesis Dan Uji In Silico Senyawa 3-(Naftalen-2-Il)-5-(2-Nitrofenil)-1-Fenil-4,5-Dihidro-1h-Pirazol Sebagai Kandidat Antikanker Payudara Dan Serviks

---

Pyrazoline is a group of heterocyclic compounds derived from dihydropyrazole with one endocyclic double bond that possesses various biological activities, including as an anticancer agent. This research synthesized the pyrazoline compound 3-(naphthalen-2-yl)-5-(2-nitrophenyl)-1-phenyl-4,5- dihydro-1H-pyrazole (PFH-2NFT-2NO2) and evaluated its potential as a breast and cervical anticancer agent. The synthesis of PFH-2NFT-2NO2 was successfully carried out through two reaction stages, the formation of chalcone compound by stirring at room temperature, followed by the synthesis of the target compound PFH-2NFT-2NO2 using a stirring method at 70-80°C for six hours, which yielded a 93.1% product. Compound purity was determined through melting point measurement (173-174°C), thin-layer chromatography (TLC) analysis, and high- performance liquid chromatography (HPLC). Structure confirmation was performed through UV spectroscopy, FTIR, MS, 1H-NMR, and 13C-NMR characterization. The anticancer activity of PFH-2NFT-2NO2 was tested using an in silico approach with molecular docking methods against estrogen-α and SIRT1 receptors. The results showed binding free energy (∆Gbind) values of -9.86 kcal/mol and an inhibition constant (Ki) of 5.93 × 10-2 µM for the estrogen-α receptor, while
∆Gbind of -12.42 kcal/mol and Ki of 7.87 × 10-4 µM were observed for the SIRT1 receptor. This analysis indicated that the PFH-2NFT-2NO2 compound showed greater potential in inhibiting cervical cancer compared to breast cancer.

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

2103110636

Penerbit

Pekanbaru : Universitas Riau FMIPA Kimia., 2025

Deskripsi Fisik

-

Bahasa

Indonesia

ISBN/ISSN

-

Klasifikasi

2103110636

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

KIMIA

Info Detail Spesifik

-

Pernyataan Tanggungjawab

Mutia

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar